Crystal form of dabrafenib and preparation method and use thereof
View Patent ↗The invention relates to Crystal Form VII of dabrafenib and preparation method thereof, wherein Crystal Form VII has the advantage of being more stable at room temperature or in aqueous systems, and has low hygroscopicity, and thus is more suitable for a wet granulation process or being prepared into a suspension; and the present invention also relates to a pharmaceutical composition and formulations comprising Crystal Form VII, and their use in the treatment of Raf family kinase-related diseases.
1. Crystal Form VII of Dabrafenib with the structural formula shown below,
characterized by a X-ray powder diffraction pattern measured using Cu-Kα radiation having the specific peaks at the diffraction angle 2θ of 7.9±0.2°, 14.5±0.2°, 19.4±0.2° and 24.3±0.2°.
2. The Crystal Form VII of Dabrafenib according to claim 1 , characterized by a X-ray powder diffraction pattern having the specific peaks at the diffraction angle 2θ of 7.9±0.2°, 11.6±0.2°, 14.5±0.2°, 17.7±0.2°, 19.4±0.2°, 20.6±0.2°, 24.3±0.2°, 27.8±0.2°, 29.2±0.2°, 30.1±0.2° and 32.6±0.2°.
3. The Crystal Form VII of Dabrafenib according to claim 2 , characterized by a X-ray powder diffraction pattern having the specific peaks at the diffraction angle 2θ of 7.9±0.2°, 11.6±0.2°, 13.7±0.2°, 14.5±0.2°, 16.3±0.2°, 17.7±0.2°, 19.4±0.2°, 20.6±0.2°, 24.3±0.2°, 25.3±0.2°, 25.5±0.2°, 27.8±0.2°, 29.2±0.2°, 30.1±0.2° and 32.6±0.2°.
4. The Crystal Form VII of Dabrafenib according to claim 3 , characterized by a X-ray powder diffraction pattern having the following specific peaks at the diffraction angle 2θ and their relative intensities:
diffraction angle
relative intensity
2θ
%
7.9 ± 0.2°
34.2
11.6 ± 0.2°
16.2
13.7 ± 0.2°
6.7
14.5 ± 0.2°
38.1
16.3 ± 0.2°
6.7
17.7 ± 0.2°
15.1
19.4 ± 0.2°
27.6
20.6 ± 0.2°
12.9
24.3 ± 0.2°
100.0
25.3 ± 0.2°
6.6
25.5 ± 0.2°
5.9
27.8 ± 0.2°
14.8
29.2 ± 0.2°
11.4
30.1 ± 0.2°
9.2
32.6 ± 0.2°
7.5.
5. A method of preparing the Crystal Form VII of Dabrafenib according to claim 1 , comprising:
(1) At room temperature, adding water or a C 5 ˜C 8 alkane into a solution formed by a known crystal form or an amorphous form of Dabrafenib in an organic solvent, stirring to crystallize for 1˜60 mins, separating and drying the precipitated crystals to get Crystal Form VII of Dabrafenib, wherein the organic solvent is selected from the group consisting of ethyl ether, 1,4-dioxane and C 2 ˜C 3 alcohols; or
(2) At room temperature, placing an isopropyl acetate solution of a known crystal form or an amorphous form of Dabrafenib in a sealed atmosphere full of a diffusive solvent to crystallize, separating and drying the precipitated crystal to get Crystal Form VII of Dabrafenib, wherein the diffusive solvent is a volatile ether solvent; or
(3) At room temperature, putting an amorphous form of Dabrafenib into a C 3 ˜C 4 alcohol to form a suspension, stirring to crystallize, separating and drying the precipitated crystal to get Crystal Form VII of Dabrafenib; or
(4) Raising the temperature of Crystal Form VI of Dabrafenib until it is completely removed of crystal water, then cooling naturally to room temperature to get Crystal Form VII of Dabrafenib; or
(5) Volatilizing a clear ethyl acetate solution of a known crystal form or an amorphous form of Dabrafenib to crystallize, separating and drying the precipitated crystals to get Crystal Form VII of Dabrafenib.
6. A pharmaceutical composition comprising a therapeutically effective amount of Crystal Form VII of Dabrafenib for inhibiting one or more raf-family kinases and at least a pharmaceutical acceptable excipient, wherein the Crystal Form VII of Dabrafenib is characterized by a X-ray powder diffraction pattern measured using Cu-Kα radiation having the specific peaks at the diffraction angle 2θ of 7.9±0.2°, 14.5±0.2°, 19.4±0.2° and 24.3±0.2°.
7. The pharmaceutical composition according to claim 6 , wherein the pharmaceutical composition is in a dosage form selected from the group consisting of tablets, capsules, suspensions, disintegrating tablets, immediate release tablets, slow release tablets and controlled release tablets.
8. The method according to claim 5 , wherein in (1), the organic solvent is selected from the group consisting of ethanol, isopropanol, ethyl ether, and 1,4-dioxanes; the C 5 ˜C 8 alkane is selected from cyclohexane, methyl cyclohexane, n-hexane, n-heptane, and mixtures thereof; and the volume ratio of water or a C 5 ˜C 8 alkane to the organic solvent is between 0.1:1 and 100:1.
9. The method according to claim 5 , wherein in (2), the diffusive solvent is mineral ether or isopropyl ether; the concentration of isopropyl acetate solution is between 0.1 and 5 mg/mL; and the duration of crystallization is between 1 and 3 weeks.
10. The method according to claim 5 , wherein in (3), the amount of the amorphous form of Dabrafenib is between 1.1 and 20 times of its solubility in the C 3 ˜C 4 alcohol at room temperature; and the duration of crystallizing is between 0.1 and 10 hours.
11. A method for inhibiting one or more Raf-family kinases comprising administering to a mammalian subject an effective amount of Crystal Form VII of Dabrafenib for inhibiting one or more raf-family kinases according to claim 1 .
12. A method for inhibiting one or more Raf-family kinases comprising administering to a mammalian subject a therapeutically effective amount of the pharmaceutical composition for inhibiting one or more raf-family kinases according to claim 6 .
13. A method of treating a disease associated with one or more Raf-family kinases comprising administering to a mammalian subject in need thereof an effective amount of Crystal Form VII of Dabrafenib according to claim 1 , wherein the disease is melanoma.
14. A method of treating a disease associated with one or more Raf-family kinases comprising administering to a mammalian subject in need thereof a therapeutically effective amount of the pharmaceutical composition according to claim 6 , wherein the disease is melanoma.